What if the next phase of the obesity-drug race is not about losing more weight, but about losing the right tissue.
That is the interesting part of Regeneron’s myostatin and activin A program. The obvious story is that the company is trying to add muscle-preserving antibodies to GLP-1 therapy. The more important story is that obesity medicine is slowly being forced to move beyond the scale.
A lower body weight can be useful. For many people it is clinically meaningful. But healthspan lives in muscle, function, metabolic resilience, mobility, strength, cardiovascular risk, independence, and the ability to recover from stress, not on the number shown on a bathroom scale.
This is why Regeneron’s program is worth watching. It is a test of whether the industry can make weight loss more biologically selective and sustainable.
The problem hiding inside successful weight loss
Modern GLP-1 and incretin therapies have changed obesity treatment. Semaglutide and tirzepatide made double-digit weight loss pharmacologically plausible for large populations. That is a real clinical shift.
But large weight loss is not tissue-specific. Fat mass falls, but lean mass falls too. Some of that lean-mass reduction may be expected when total body size decreases. Some may be clinically less important than the headline suggests. Muscle loss can be mitigated by protein rich diets and strength training. But this does not solve the problem entirely. So, for a longevity audience, the question matters: if we use long-term pharmacology to reduce weight, what happens to the tissue that protects people from frailty?
Regeneron’s answer is to pair semaglutide with antibodies that block two negative regulators of muscle growth: myostatin, also known as GDF8, and activin A.
The company’s lead muscle-preservation asset is trevogrumab, an anti-myostatin antibody. The second is garetosmab, an anti-activin A antibody. The biology is not random. Myostatin and activin signaling act as brakes on muscle growth. Remove part of the brake, and muscle mass can increase. Remove more of the brake, and the effect may be larger.
What Regeneron reported
In September 2025, Regeneron reported Phase 2 COURAGE results in adults with obesity [1]. The trial compared semaglutide alone with semaglutide plus trevogrumab, and with a triplet combination of semaglutide, trevogrumab, and garetosmab.
The headline was not total weight loss. It was the composition of that weight loss.
At 26 weeks, Regeneron said 33% of weight loss in the semaglutide-only arm came from lean mass. Adding trevogrumab reduced that share to 16.8% at the lower dose and 18.1% at the higher dose. The triplet combination reduced lean-mass loss to 0.9 kg, or 7.4% of total weight loss, while fat-mass loss reached 11.8 kg and total body weight fell 13.4%.
Those numbers are striking because they shift the conversation from “how much weight?” to “which compartment?” That is a better question for healthspan.
The program also has mechanistic support. In a Nature Communications paper published in 2025, Regeneron researchers and collaborators reported that combined blockade of GDF8 and activin A produced greater muscle effects than blocking either pathway alone in humans, using MRI and DXA measures of muscle volume and lean mass.
Garetosmab also has a separate clinical proof point in fibrodysplasia ossificans progressiva, an ultra-rare disease where activin A drives abnormal bone formation. In the Phase 3 OPTIMA trial, Regeneron reported that garetosmab reduced new heterotopic ossification lesions by 94% and 90% at two tested doses versus placebo [3]. That does not prove obesity benefit, but it does show activin A is not just a theoretical target.
The non-obvious question: does preserved lean mass become preserved function?
Lean mass is not the same as muscle function. DXA is not a chair-rise test. MRI thigh volume is not grip strength, gait speed, fall risk, insulin sensitivity, or long-term independence.
For longevity, the clinically important question is not simply whether an antibody preserves kilograms of lean mass during GLP-1 treatment. The question is whether it preserves useful tissue in a way that changes outcomes people actually feel: strength, mobility, fatigue, glucose handling, weight maintenance, frailty risk, and quality of life.
This distinction matters because the obesity market has strong incentives to create new combination regimens. If GLP-1 drugs become chronic infrastructure, every company wants the next layer: more fat loss, less nausea, better adherence, oral dosing, muscle preservation, maintenance therapy, or cardiometabolic differentiation.
Some of those layers will be clinically useful. Some will be expensive refinements of surrogate endpoints. The line between the two will be defined by function.
A real category is forming
Regeneron is not alone. Scholar Rock’s apitegromab, a selective myostatin inhibitor, has also been studied with incretin therapy. In the EMBRAZE study reported in Nature Medicine, apitegromab preserved more lean mass during tirzepatide-induced weight loss compared with placebo, while total weight loss remained similar.
Lilly has also been active around the broader activin/myostatin biology through bimagrumab, which blocks activin type II receptors. That is a broader approach than Regeneron’s ligand-specific blockade of myostatin and activin A, and it raises a different set of selectivity and safety questions.
Taken together, the category is becoming clearer: obesity pharmacology is moving from weight loss to body-composition engineering.
That phrase should make us both interested and cautious. Interested, because losing fat while preserving muscle is directionally aligned with healthspan. Cautious, because engineering body composition pharmacologically is not the same as creating durable metabolic health.
The healthspan lens
From a longevity perspective, muscle is not cosmetic. It is a reserve system. It stores glucose, supports movement, protects against frailty, helps people recover from illness, and gives older adults a buffer against decline.
That is why muscle-preserving obesity drugs are more interesting than the usual weight-loss headline. They point to a better endpoint hierarchy. First: reduce excess fat mass when clinically needed. Second: preserve or improve muscle quality. Third: prove the person functions better. Fourth: show durability after the intervention is reduced, stopped, or combined with lifestyle. The bonus: make patients look better while on therapy.
Regeneron’s data are promising, but they sit mostly between the first and second steps. The field still has to prove the third and fourth.
There are also practical questions. Chronic antibody combinations could be expensive. Safety needs longer follow-up evidence. Muscle growth pathways are powerful biology, and powerful biology rarely comes without tradeoffs. Side effects, dosing burden, adherence, reimbursement, and who actually needs this level of intervention will all matter.
The better story
The Regeneron story is not “a new muscle drug for weight loss.” That is too easy.
The real story is that the GLP-1 era has exposed a weakness in how we talk about obesity treatment. We celebrate weight loss as if all lost weight is the same. It is not.
For longevity, the question is more precise: can we reduce excess fat without weakening the physical reserve people need as they age?
If the answer is yes, this becomes more than obesity pharmacology. It becomes function-preserving medicine.
The lifestyle paradox
If these drugs work, they will not make lifestyle irrelevant. They will make lifestyle more important and easier to neglect at the same time.
That is the paradox.
A drug can help preserve lean mass during weight loss, but it cannot teach someone to use that muscle. It cannot build coordination, balance, cardiovascular capacity, confidence, training habits, or the social environment that makes movement durable.
The best version of this category is not a replacement for resistance training. It is a reason to prescribe it more seriously. If medicine can reduce the biological penalty of weight loss, lifestyle should become the multiplier: the thing that turns preserved tissue into useful function.
The weaker version is more predictable. The market sells “less muscle loss” as permission to care less about protein, strength training, recovery, and long-term behavior. That would be a very expensive way to produce better-looking body-composition numbers without a matching improvement in resilience.
So the public-health question is not whether these drugs reduce personal responsibility. It is whether healthcare systems use them to support responsibility, or whether consumer culture uses them to bypass it.